Critical Role for 24-Hydroxylation in Homeostatic Regulation of Vitamin D Metabolism

Zhinous Shahidzadeh Yazdi, Elizabeth A. Streeten, Hilary B. Whitlatch,

May E. Montasser, Amber L. Beitelshees, and Simeon I. Taylor

Department of Medicine

Division of Endocrinology, Diabetes, and Nutrition

University of Maryland School of Medicine

Baltimore, MD, USA

Corresponding author: Simeon I. Taylor, MD, PhD, Department of Medicine, University of

Maryland School of Medicine, Baltimore, MD 21201, USA

Telephone number: +1 301 980 5272

Email: staylor2@som.umaryland.edu

Conflict-of-interest statement: SIT serves as a consultant for Ionis Pharmaceuticals and receives
an inventor's share of royalties from NIDDK for metreleptin as a treatment for generalized
lipodystrophy. EAS, MEM, and HBW receive research support (unrelated to this project) from
the Regeneron Genetics Center. ZSY and ALB have no conflicts to disclose.
20

Trial registration: NCT02891954 (clinicaltrials.gov)

Funding: National Institute of Diabetes, Digestive, and Kidney Diseases: R01DK118942,
R01DK118924-02S1, and T32DK098107

Key words: vitamin D deficiency, 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, 25-
hydroxyvitamin D, parathyroid hormone, homeostatic regulation

ORCID ID# (Simeon I. Taylor): 0000-0001-7500-7854

ABSTRACT

ABSTRACT

Context. The body has evolved homeostatic mechanisms to maintain free levels of Ca^{+2} and

1,25-dihydroxyvitamin D [$1,25(OH)_2D$] within narrow physiological ranges. Clinical guidelines

emphasize important contributions of PTH in maintaining this homeostasis.

Objective. To investigate mechanisms of homeostatic regulation of vitamin D (VitD) metabolism

and to apply mechanistic insights to improve clinical assessment of VitD status.

Design. Crossover clinical trial studying participants before and after VitD3-supplementation.

Setting. Community.

Participants. 11 otherwise healthy individuals with VitD-deficiency (25-hydroxyvitamin D

[$25(OH)D$] ≤ 20 ng/mL).

Interventions. VitD3-supplements (50,000 IU once or twice a week depending on BMI, for 4-6

weeks) were administered to achieve $25(OH)D \geq 30$ ng/mL.

Results. VitD3-supplementation significantly increased mean $25(OH)D$ by 2.7-fold and 24,25-

dihydroxyvitamin D [$24,25(OH)_2D$] by 4.3-fold. In contrast, mean levels of PTH, FGF23, and

$1,25(OH)_2D$ did not change in response to VitD3-supplementation. Mathematical modeling

suggested that 24-hydroxylase activity was maximal for $25(OH)D \geq 50$ ng/mL and achieved a

minimum (~90% suppression) with $25(OH)D < 10\text{-}20$ ng/mL. Suppression of 24-hydroxylase

activity was triggered by mild-moderate VitD-deficiency, which sustains physiological levels of

$1,25(OH)_2D$ by suppressing metabolic clearance of $1,25(OH)_2D$. VitD metabolite ratios [e.g.,

$1,25(OH)_2D/24,25(OH)_2D$] provide useful indices of VitD status. When VitD availability is

limited, this suppresses 24-hydroxylase activity – thereby decreasing the level of $24,25(OH)_2D$

and increasing the $1,25(OH)_2D/24,25(OH)_2D$ ratio. Thus, a high $1,25(OH)_2D/24,25(OH)_2D$ ratio

signifies triggering of homeostatic regulation in response to mild-moderate VitD-deficiency.

Conclusions. Suppression of 24-hydroxylase activity provides a first line of defense against

symptomatic VitD-deficiency by decreasing metabolic clearance of $1,25(OH)_2D$. The

$1,25(OH)_2D/24,25(OH)_2D$ ratio can provide a useful index of clinical VitD status.

INTRODUCTION:

Vitamin D (VitD) plays an essential role in mediating absorption of dietary calcium in the intestine (1-4). Furthermore, as evidenced by diseases such as nutritional rickets, VitD is critical to maintaining bone health (5, 6). The body obtains VitD from two sources. Endogenous production of VitD requires exposure to ultraviolet light, which is variable depending on geographic location and the season of the year among other factors. Dietary intake of VitD is also variable and depends on the VitD content of the diet (including intake of fortified dairy products and dietary supplements) (7, 8). To maintain a consistent *milieu intérieure* (9, 10), each individual must maintain levels of free 1,25-dihydroxyvitamin D [$1,25(OH)_2D$] – the biologically active metabolite of VitD – within a narrow physiological range notwithstanding considerable variation in availability of the biosynthetic precursor (i.e., VitD) (11-13).

We developed a mathematical model to investigate physiological mechanisms mediating homeostatic regulation of VitD metabolism. 24-hydroxylation provides the major mechanism whereby $1,25(OH)_2D$ is cleared (12, 14, 15). According to our mathematical model, *in vivo* activity of 24-hydroxylase varies over an approximately tenfold range. 24-Hydroxylase activity achieves a maximum when 25(OH)D levels exceed 50 ng/mL. By inducing 24-hydroxylase activity when VitD is abundant, the body increases clearance of $1,25(OH)_2D$ – thereby protecting against VitD toxicity. Furthermore, the model suggests that 24-hydroxylase activity achieves a minimum when 25(OH)D is less than 10-20 ng/mL. The resultant decrease in $1,25(OH)_2D$ clearance tends to sustain $1,25(OH)_2D$ levels, thereby compensating for limited availability of VitD and protecting against symptomatic VitD deficiency.

Several feedback loops contribute to homeostatic regulation of VitD – including feedback loops between VitD status and the rates of both production and clearance of $1,25(OH)_2D$ (12, 16-19).

Cannon proposed the concept of the "wisdom of the body" (9), which includes homeostatic

mechanisms that are responsible for maintaining a constant *milieu intérieure.* Endocrinologists

often leverage the "wisdom of the body" to diagnose states of hormonal excess or hormonal

insufficiency based on the level of activation or suppression of homeostatic mechanisms. This is

exemplified by the approach to diagnosing patients' hormonal status with respect to hormones

that act upon other nuclear hormone receptors (e.g., thyroid hormones or glucocorticoids) by

measuring the levels of trophic hormones (e.g., TSH or ACTH) (20, 21). By analogy, we discuss

our data in the context of the published literature advocating for a similar approach to assessing

VitD status – i.e., by assessing the level of suppression/induction of 24-hydroxylase activity (22-

24). By leveraging the wisdom of the body in this assessment, physicians can advance the state-

of-the-art of assessment of VitD status.

METHODS

This study ("VitD Sub-study") was part of our ongoing "Genetics of Response to Canagliflozin (GRC)" clinical trial (Clinicaltrials.gov Identifier: NCT02891954) in healthy volunteers recruited from the Old Order Amish population in Lancaster PA, who are non-Hispanic white people. Although participants were excluded from the parent study if their 25(OH)D level ≤20 ng/mL, these VitD deficient individuals were eligible to participate in the VitD Sub-study, which investigated the effects of VitD3 supplements on canagliflozin-triggered changes in the serum phosphorus/FGF23/1,25(OH)$_2$D/PTH axis (13). Participants were required to meet all other inclusion/exclusion criteria for the parent study. The effect of VitD3 supplementation on canagliflozin-induced changes in mineral metabolism biomarkers was reported elsewhere (13). The current paper reports results of a secondary data analysis focusing primarily on the effect VitD3 supplementation on VitD metabolites in participants with mild-moderate VitD deficiency.

Screening and recruitment:

As reported previously, we screened 24 healthy volunteers from September 2019 to July 2021 and enrolled 19 individuals with 25(OH)D levels ≤20 ng/mL who were otherwise eligible to participate in the parent GRC study (13). The Endocrine Society's clinical practice guidelines proposed thresholds of 25(OH)D ≤20 ng/mL (≤50 nmol/L) for VitD deficiency, 21-29 ng/mL (51-74 nmol/L) for VitD insufficiency, and ≥ 30 ng/mL (≥75 nmol/L) for VitD sufficiency (17). We applied The Endocrine Society's definition of VitD deficiency (≤20 ng/mL) as a key inclusion criterion for this sub-study and applied the definition of VitD sufficiency (≥30 ng/mL) as the criterion for adequacy of VitD3 supplementation. Details of demographics, baseline characteristics, recruitment, and disposition are reported elsewhere (13). Because of interruptions and delays associated with the COVID-19 pandemic, we did not complete our plan to study 25

research participants. We analyzed data after eleven participants (four females and seven males)

completed the entire study protocol.

Endpoints and biomarkers:

We measured levels of the following biomarkers both at baseline and after VitD3

supplementation: plasma PTH, plasma FGF23, serum phosphorus, serum calcium, and three

VitD metabolites – 25(OH)D, 1,25(OH)$_2$D, and 24,25-dihydroxyvitamin D [24,25(OH)$_2$D].

VitD3 supplementation protocol

VitD deficient participants completed canagliflozin challenge #1 and then received VitD3

capsules (Bio-Tech Pharmacal; Fayetteville, AR) in doses of either 50,000 IU per week for

participants with BMI <30 kg/m^2 or 50,000 IU twice a week for participants with BMI ≥30 kg/m

for four weeks, followed by a second total serum 25(OH)D measurement a week after

completion of the four-week VitD3 supplementation protocol (13). If screening serum 25(OH)D

levels (Quest Diagnostics) were <30 ng/mL, high-dose VitD3 supplementation was continued.

Once screening 25(OH)D (Quest Diagnostics) levels were confirmed to be ≥30 ng/mL,

maintenance-dose VitD3 supplementation (1000 IU/d or 2000 IU/d for BMI <30 kg/m^2 or BMI

≥30 kg/m^2, respectively) was continued until completion of canagliflozin challenge #2.

Clinical chemistry

Blood samples obtained at home visits were collected in test tubes as appropriate for each assay

(13). Quest Diagnostics conducted an immunoassay for baseline levels of plasma PTH as well as

LC-MS/MS assays to measure baseline serum 1,25(OH)$_2$D, and serum 25(OH)D levels. Plasma

levels of 25(OH)D and 24,25(OH)$_2$D were assessed using LC-MS/MS assays conducted by

Heartland Assays (Ames, IA). Quest's serum 25(OH)D levels were used to determine eligibility

for the VitD Sub-study. Heartland's plasma 25(OH)D levels were used to assess the response to

VitD3 supplements. We have reported 25(OH)D and 24,25(OH)$_2$D in ng/mL and 1,25(OH)$_2$D in

pg/mL. Multiplication by a factor of 2.49 can be used to convert from ng/mL to nmol/L. Mean

levels for 25(OH)D before and after VitD3 supplementation, were identical in assays conducted

by Quest Diagnostics and Heartland Assays (13). LC-MS/MS assays conducted at both Quest

Diagnostics and Heartland Assays distinguished between derivatives of VitD2 and VitD3.

Derivatives of VitD2 were not detected in any of our participants' samples. For simplicity, we

refer to our data on levels of 25(OH)D, 1,25(OH)$_2$D, or 24,25(OH)$_2$D without specifying D2 or

D3. Nevertheless, since D2 derivatives were not detected in any of our participants, this should

be understood as referring exclusively to D3 derivatives.

Quality control for VitD assays of VitD metabolites

Heartland Assays provided the following information regarding their assays of VitD metabolites:

25(OH)D and 24,25(OH)$_2$D. Accuracy >90% based on comparisons to National Institute of

Standards and Technology standards. Coefficients of variation for both inter- and intra-assay

were < 5%.

Analysis of our data. We obtained blood samples on three separate days during canagliflozin

(300 mg/day) challenge tests: baseline prior to receiving canagliflozin, at 48 hours (after

receiving canagliflozin for two days), and at 120 hours (after receiving canagliflozin for five

days). Because mean levels of 25(OH)D and 24,25(OH)$_2$D were not affected by canagliflozin,

we calculated coefficients of variation based on an assumption that the three separate blood

samples obtained from each individual during the canagliflozin challenge test had similar

concentrations of those two VitD metabolites. Based on this assumption, we calculated

coefficients of variation of 5.8% for 25(OH)D and 11.1% for 24,25(OH)$_2$D. Because these

calculated coefficients of variation included day-to-day variation in VitD metabolite levels as

well as intra-assay variation, our estimates of coefficients of variation are likely greater than the

actual intra-assay variation.

Furthermore, we compared mean data for 25(OH)D levels measured in the same individuals in

the two assays. Mean 25(OH)D levels before receiving VitD3 supplements were 16.4 and 16.5

ng/mL in the Quest and Heartland assays, respectively (13). Mean total 25(OH)D levels after

receiving VitD3 supplements were 45.3 and 44.3 ng/mL in the Quest and Heartland assays,

respectively (13). In addition, the individual data from the Quest assay (blood obtained on the

day of screening) was highly correlated with individual data from the Heartland assay (blood

obtained on Day 1 of the canagliflozin challenge test) – with variance in one assay accounting

for 81% of the variance in the other assay. Based on these data, we conclude that the two assays

provide comparable measurements of 25(OH)D levels. In any case, the Quest assay for 25(OH)D

was used only to determine eligibility for the study. The Heartland assay was the sole source of

data on 25(OH)D levels used for determination of goodness-of-fit for our model.

Published analysis of Quest's assay of 1,25(OH)$_2$D. Biancuzzo et al. (25) reported intra- and

inter-assay coefficients of variation of 9% and 12%, respectively, for Quest's assay of

1,25(OH)$_2$D. In addition, we estimated the inter-assay coefficient of variation based on our

observation that 1,25(OH)$_2$D levels were not changed by administration of VitD3 supplements.

When we calculated a coefficient of variation for 1,25(OH)$_2$D levels before and after VitD3

supplementation, we estimated a coefficient of variation of 13% – very similar to the inter-assay

coefficient of variation reported by Biancuzzo et al. (25). Our calculation of coefficient of

variation includes at least three components: the coefficient of variation for measurement error,

day-to-day variation, and a possible small effect of VitD3 supplementation on $1,25(OH)_2D$

levels. Thus, our estimate of the coefficient of variation represents an upper bound for the actual

inter-assay coefficient of variation.

Mathematical Modeling

We developed a mathematical model to analyze relationships among $25(OH)D$, $1,25(OH)_2D$, and

$24,25(OH)_2D$. See Table 1 for definitions of model parameters. For the purpose of fitting curves

to model our clinical trial data, we estimated model parameters using an iterative trial and error

approach.

The observed sigmoid curve expressing the concentration of total $24,25(OH)_2D$ as a function of

total $25(OH)D$ was fitted by an equation with the form of Equation (1):

$$(1) \quad S(24,25) = \frac{(\frac{W24}{L24})e^{aS(25)}}{1+\frac{e^{aS(25)}}{L24}}$$

where $S(25)$ and $S(24,25)$ represent levels of $25(OH)D$ and $24,25(OH)_2D$, respectively; W_{24} and

L_{24} represent analogs of the maximal velocity and Michaelis-Menten constant for 24-

hydroxylase enzyme, respectively, with $25(OH)D$ as substrate; α is a model parameter to

facilitate fitting the equation to the observed data.

The model assumes that $24,25(OH)_2D$ is cleared by a first order process with a rate constant of

m(24,25) [Equation (1a)]:

$$(1a) \ Rate \ of \ clearance \ of \ 24,25(OH)_2D = m(24,25)\frac{(\frac{W24}{L24})e^{aS(25)}}{1+\frac{e^{aS(25)}}{L24}}$$

We hypothesized that the 24-hydroxylase enzyme follows Michaelis-Menten kinetics as

described by Equation (2):

$(2)\ Production\ of\ 24,25(OH)_2D = \dfrac{V24 \times h \times S(25)}{K24 + S(25)}$

where $S(25)$ represents the level of 25(OH)D; V_{24} and K_{24} represent the maximal velocity and

Michaelis-Menten constant for 24-hydroxylase enzyme, respectively, with 25(OH)D as substrate.

h is a variable function of $S(25)$ that represents 24-hydroxylase activity as a fraction of the

maximally induced level of the enzyme observed when 25(OH)D levels are high.

At steady state, the rate of production of 24,25(OH)$_2$D [Equation (2)] is equal to the rate at which

24,25(OH)$_2$D is cleared [Equation (1a)]. Accordingly, the value of h can be calculated by

Equation (3):

$(3)\ h = m(24,25)\dfrac{(\frac{W24}{L24})e^{aS(25)}}{1+\frac{e^{aS(25)}}{L24}} \div \dfrac{V24 \times S(25)}{K24 + S(25)}$

Genetic evidence demonstrates the critical role of CYP24A1-mediated 24-hydroxylation in

inactivation of 1,25(OH)$_2$D (26, 27). Homozygosity for loss of function mutations in *CYP24A1*

has been reported to cause hypercalcemia – presumably due to excessive levels of 1,25(OH)$_2$D.

Since CYP24A1 catalyzes 24-hydroxylation of both 25(OH)D and 1,25(OH)$_2$D, we modified

Equation (1a) to yield Equation (4):

$(4)\ Rate\ of\ clearance\ of\ 1,25(OH)_2D = m(1,25)\dfrac{(\frac{W1,25}{L1,25})e^{aS(1,25)}}{1+\frac{e^{aS(1,25)}}{L1,25}}$

where $S(1,25)$ represents the level of 1,25(OH)$_2$D; $W_{1,25}$ and $L_{1,25}$ represent analogs of the

maximal velocity and Michaelis-Menten constant for 24-hydroxylase enzyme, respectively, with

1,25(OH)$_2$D as substrate; α is a model parameter that facilitates fitting the equation to the

observed data; and $m(1,25)$ is a first-order rate constant analogous to $m(24,25)$ in Equation (1a).

Further, we hypothesize that CYP27B1-mediated 1α-hydroxylation of 25(OH)D follows

Michaelis-Menten kinetics:

$\quad$ (5) $Production\ of\ 1,25(OH)_2D = \dfrac{V1 \times S(25)}{K1 + S(25)}$

where V_1 and K_1 represent the maximal velocity and Michaelis-Menten constant for 1α-

hydroxylase, respectively, with 25(OH)D as substrate. Under steady state conditions, the rates of

production and metabolic clearance of 1,25(OH)$_2$D are equal. Thus, we can combine Equations

(4) and (5) to yield Equation (6):

$\quad$ (6) $\dfrac{V1 \times S(25)}{K1 + S(25)} = m(1,25) \dfrac{(\frac{W1,25}{L1,25})e^{aS(1,25)}}{1 + \frac{e^{aS(1,25)}}{L1,25}}$

Solving for $S(1,25)$, we obtain Equation (7):

$\quad$ (7) $S(1,25) = \left\{ Ln[S(25)] - Ln\left[m_{1,25} + \dfrac{S(25)}{K_1}\left(m_{1,25} - \dfrac{V_1}{W_{1,25}} \right) \right] - Ln\dfrac{W_{1,25}K_1}{L_{1,25}V_1} \right\}/a$

Goodness of fit

We calculated the following metrics in order to evaluate the goodness of fit between our

mathematical model and the experimental data:

Sum of squares due to regression: $\boldsymbol{SSR} = \sum(\widehat{\boldsymbol{x}}_i - \overline{\boldsymbol{x}})^2$

Total sum of squares about the mean: $\boldsymbol{SST} = \sum(\boldsymbol{x}_i - \overline{\boldsymbol{x}})^2$

Sum of squared errors: $\boldsymbol{SSE} = \sum(\boldsymbol{x}_i - \widehat{\boldsymbol{x}}_i)^2$

Data on goodness of fit is provided in the Results section as appropriate.

Estimating relative 24-hydroxylase activity

Equation (3) expresses relative 24-hydroxylase activity (h) as a function of the 25(OH)D level.

However, total 25(OH)D levels are affected by inter-individual variation in VDBP levels, a

factor which is not included in our model. Accordingly, we replaced 25(OH)D levels by the ratio

of 25(OH)D/1,25(OH)$_2$D. The 25(OH)D/1,25(OH)$_2$D ratio is independent of VDBP level and

provides an index of free levels of 25(OH)D. To normalize values of this ratio to correspond to

values of total 25(OH)D, we first divided individual values of the 25(OH)D/1,25(OH)$_2$D by a

normalization factor [the mean value of the 25(OH)D/1,25(OH)$_2$D ratio before administration of

VitD3 supplements]. We next converted individual values of the normalized

25(OH)D/1,25(OH)$_2$D ratio to the same units as total 25(OH)D by multiplying by a conversion

factor [the mean value of 25(OH)D before administration of VitD3 supplements].

Statistics

A two-sided p-value <0.05 (paired t-test) was taken as the threshold for statistical significance

without any correction for multiple comparisons. We pooled all the data before and after VitD3

supplementation for graphing total levels of 1,25(OH)$_2$D and 24,25(OH)$_2$D as a function of total

levels of 25(OH)D. Both Pearson and Spearman correlation coefficients were calculated using

software provided in Excel.

Study approval

The Clinical Trial Protocol was approved by the University of Maryland Baltimore Institutional

Review Board (FWA00007145). Written informed consent was obtained from all participants.

RESULTS

Herein we report results of a secondary analysis of data obtained in our published clinical trial investigating pharmacodynamic nutrient-drug interactions between VitD and canagliflozin (13). We applied mathematical modeling to investigate the effects of VitD3 supplementation on homeostatic regulation of VitD metabolite levels. The details of the mathematical model are summarized in the Methods section.

Interrelationships among $1,25(OH)_2D$, $24,25(OH)_2D$, and $25(OH)D$.

As reported previously, mean (±SEM) total plasma levels of both $25(OH)D$ and $24,25(OH)_2D$ increased significantly in response to VitD3 supplementation: from 16.5±1.6 to 44.3±5.5 ng/mL (p=0.0006) for $25(OH)D$ and from 1.0±0.1 to 4.3±0.6 ng/mL (p=0.0002) for $24,25(OH)_2D$ (13). We observed consistent increases in total levels of $25(OH)D$ and $24,25(OH)_2D$ (Figs. 1A and 1B). In contrast, mean total plasma levels of $1,25(OH)_2D$ did not change in response to VitD3 supplements (43.8±3.6 pg/mL versus 44.9±4.1 pg/mL; p=0.7) (Fig. 1C) (13). This observation provides strong evidence of the effectiveness of homeostatic mechanisms regulating levels of $1,25(OH)_2D$. Therefore, we conducted exploratory analyses to further investigate physiological mechanisms mediating this homeostatic regulation.

For this analysis, we pooled data on VitD metabolites – including data obtained both before and after VitD3 supplementation (Fig. 2). Although there was no significant correlation between total plasma levels of $1,25(OH)_2D$ and $25(OH)D$ (Fig. 2A), total plasma levels of $24,25(OH)_2D$ increased as a function of total plasma $25(OH)D$ levels (Fig. 2B).

A critical role for regulation of 24-hydroxylase activity in homeostatic regulation of $1,25(OH)_2D$

We considered possible mechanisms that might contribute to the observed sigmoid shape of the

curve relating total 24,25(OH)$_2$D levels to total 25(OH)D levels (Fig. 2B). If the 24-hydroxylase

enzyme (CYP24A1) followed simple Michaelis-Menten kinetics, one might have predicted that

the relationship between plasma levels of 24,25(OH)$_2$D and 25(OH)D would have been

described by a hyperbola (Fig. 3A, solid curve) rather than a sigmoid curve (Fig. 3A, dashed

curve). The observed sigmoid curve approaches an asymptote at high levels of 25(OH)D – most

likely a reflection of the saturability of the 24-hydroxylase enzyme (CYP24A1). What can

explain the relative underproduction of 24,25(OH)$_2$D at low levels of 25(OH)D as compared to

what would have been predicted by simple Michaelis-Menten kinetics? As suggested by others

(18, 23, 28), we hypothesized that expression of 24-hydroxylase enzyme is regulated, with low

24-hydroxylase activity occurring when 25(OH)D levels are low and higher 24-hydroxylase

activity when 25(OH)D levels are high. We applied mathematical modeling (see Methods

section) to provide quantitative estimates of the relationship between activity of the 24-

hydroxylase enzyme and 25(OH)D levels (Fig. 3C). Our model suggests that 24-hydroxylase

activity achieves a maximum when 25(OH)D levels exceed 50 ng/mL. In contrast, VitD

deficiency is associated with suppression of 24-hydroxylase activity– achieving a minimum

corresponding to ~90% suppression when 25(OH)D levels are less than 10-20 ng/mL. Our

mathematical model provides estimates of 24-hydroxylase activity as a function of 25(OH)D

levels (Fig. 3C). The data points in Fig. 2A demonstrate substantial "scatter" around the modeled

curve. We hypothesize that the ~3-fold range of inter-individual variation in levels of VitD

binding protein (VDBP) (29) may account for the observed 3.4-fold range of total levels of

1,25(OH)$_2$D observed in this study, which in turn could account for the observed scatter for data

points in the plot of total levels of 1,25(OH)$_2$D versus total levels of 25(OH)D (Fig. 2A).

Interestingly, the modeled curve predicts that levels of 1,25(OH)$_2$D begin to decrease slightly for

levels of 25(OH)D < ~15-20 ng/mL. This "fall-off" may possibly be related to the fact that the

model does not account for development of secondary hyperparathyroidism. If the model

specified that low levels of 25(OH)D would trigger increased secretion of PTH and resultant

increased 1α-hydroxylation of 25(OH)D, it is likely that the model would predict constant levels

of 1,25(OH)$_2$D for lower levels of 25(OH)D.

Validating the model using the goodness of fit

Equation (1) provides a good fit to the observed data as shown by the graph plotting total levels

of 24,25(OH)$_2$D as a function of 25(OH)D (Fig. 2B). Goodness of fit is evidenced by the fact

that the sum of the squared errors (SSE) is small relative to the total sum of the squares about the

mean (SST): SSE/SST = 0.078 (Table 2).

Moreover, equation (7) correctly predicts that 1,25(OH)$_2$D levels are not correlated with

25(OH)D levels (Fig. 2A). Indeed, the sum of the squared errors (SSE) is approximately equal to

the total sum of the squares about the mean (SST): SSE/SST = 1.04 (Table 2). Furthermore, the

value of the ratio of the sum of the squares due to regression (SSR) divided by SST = 0.094,

suggesting that a horizontal line described by the following equation provides a good fit for the

observed data: 1,25(OH)$_2$D = 44.4 pg/mL (i.e., with 44.4 pg/mL being the mean level of

1,25(OH)$_2$D).

VitD metabolite ratios are better predictive of clinical VitD status

As noted in the literature, ratios of VitD metabolites are relatively independent of inter-individual

variation in VDBP levels (24, 30, 31). For example, the following equations demonstrate that the

ratio of [1,25(OH)$_2$D]/[24,25(OH)$_2$D] is independent of VDBP levels:

(8) $[1,25(OH)_2D]_{total} \approx [1,25(OH)_2D]_{free} \times VDBP_{total} \times K_{1,25}$

(9) $[24,25(OH)_2D]_{total} \approx [24,25(OH)_2D]_{free} \times VDBP_{total} \times K_{24,25}$

(10) $\dfrac{[1,25(OH)_2D]_{total}}{[24,25(OH)_2D]_{total}} \approx \dfrac{[1,25(OH)_2D]_{free}}{[24,25(OH)_2D]_{free}} \times \dfrac{K_{1,25}}{K_{24,25}}$

When the $\dfrac{[1,25(OH)_2D]_{total}}{[24,25(OH)_2D]_{total}}$ ratio is plotted as a function of total levels of 25(OH)D, this

represents a graph of a VDBP-independent variable on the y-axis and a VDBP-dependent

variable on the x-axis (Fig. 4A). In contrast, the graph of $\dfrac{[1,25(OH)_2D]_{total}}{[24,25(OH)_2D]_{total}}$ as a function of

$\dfrac{[25(OH)D]_{total}}{[1,25(OH)_2D]_{total}}$ plots VDBP-independent variables on both axes (Figs. 4B). This approach

minimized the contribution of inter-individual variation in VDBP levels, thereby minimizing

"scatter" of points in the graph (Fig. 4B). When $\dfrac{[1,25(OH)_2D]_{total}}{[24,25(OH)_2D]_{total}}$ was plotted as a function of

$\dfrac{[25(OH)D]_{total}}{[1,25(OH)_2D]_{total}}$, the absolute value of the Spearman correlation coefficient was quite high ($\rho=-$

0.94; $p=10^{-10}$) (Fig. 4B). In contrast, the absolute value of the Spearman correlation coefficient

was lower ($\rho=-0.83$; $p=2.2 \times 10^{-6}$) when $\dfrac{[1,25(OH)_2D]_{total}}{[24,25(OH)_2D]_{total}}$ was plotted as a function of total levels

of 25(OH)D (Fig. 4A).

Modeling VitD Metabolite Ratios

Tang et al. (23) proposed that the ratio of 1,25(OH)2D/24,25(OH)2D provides an improved

assessment of clinical VitD status with a ratio ≥ 51 suggesting "VitD deficiency" and a ratio of

35-50 suggesting "VitD insufficiency". We applied our mathematical model to predict the shape

of the curve expressing Tang's VitD metabolite ratio (1,25(OH)2D/1,24(OH)2D) as a function of

total levels of 25(OH)D. Our modeled curve (Fig. 4A) closely resembles the curve included in

the publication by Tang et al. (23). Based on our modeled curve, the cutoffs proposed by Tang et

al. correspond to total 25(OH)D levels of ~17 ng/mL for "VitD deficiency" and ~21 ng/mL for

"VitD insufficiency".

Furthermore, our mathematical model provides a good fit to the observed data as shown by the

graph plotting total levels of $1,25(OH)_2D/24,25(OH)_2D$ as a function of 25(OH)D (Fig. 4A). Two

other VitD metabolite ratios have been proposed in the literature: $1,25(OH)_2D/25(OH)D$ (32) and

$24,25(OH)_2D/25(OH)D$ (24, 30, 31, 33, 34). Our mathematical model predicts that the

$25(OH)D/1,25(OH)_2D$ ratio [i.e., the reciprocal of the $1,25(OH)_2D/25(OH)D$ ratio proposed in

the literature (32)] is a near-linear function of 25(OH)D levels (Fig. 5A); the graph of the

$24,25(OH)_2D/25(OH)D$ ratio versus 25(OH)D is predicted to be a sigmoid curve (Fig. 5B). The

modeled curves for all three VitD metabolite ratios provide good fits to observed data [SSE/SST

ratios of 0.49-0.52 (Table 2)].

Correlation of relative 24-hydroxylase activity (h) with VitD metabolite ratios

We pooled our data before and after VitD3 supplementation for each of the three VitD

metabolites. We first investigated the correlation of the calculated relative 24-hydroxylase

activity (h) with total 25(OH)D levels, which gave a Spearman correlation coefficient of $\rho=0.85$

(p=7E-07) (Fig. 6A). We then evaluated correlations with three VitD metabolite ratios. As

expected, relative 24-hydroxylase activity (h) was perfectly correlated with the

$25(OH)D/1,25(OH)_2D$ ratio ($\rho=1$) since this ratio was used in our model to account for the effect

of variation in VDBP (Fig. 6B). While 24-hydroxylase activity (h) was highly correlated with the

$1,25(OH)_2D/24,25(OH)_2D$ ratio ($\rho^2=0.94$; p=3E-13) (Fig. 6C), h was less well correlated with the

$24,25(OH)_2D/25(OH)$ ratio ($\rho^2=0.67$; p=3E-06) (Fig. 6D).

PTH response to VitD3 supplementation and correlation of PTH with indices of VitD status

Although baseline PTH levels were correlated with baseline total 25(OH)D levels before VitD3

supplementation (R^2=0.08; p=5E-05), the variance in 25(OH)D accounted for only 8% of the

variance in PTH. Furthermore, the slope of the regression line was positive whereas the known

physiology predicts that the slope should be negative (Fig. 7A) with PTH levels being higher

when 25(OH)D levels are lower. Moreover, baseline PTH levels were not significantly

correlated with the baseline 1,25(OH)$_2$D/24,25(OH)$_2$D ratio (R^2=0.008; p=0.63) (Fig. 7B). Even

in participants who had received VitD3 supplementation, we observed a wide range for PTH

levels (29-85 pg/ml) – suggesting that each participant has an individual setpoint for PTH levels.

Therefore, in order to normalize PTH levels relative to each individual's setpoint, we defined a

PTH index: i.e., the ratio of the PTH level before VitD3 supplementation divided by the PTH

level after VitD3 supplementation. Ten among our 11 participants exhibited PTH indices between

0.8-1.2, suggesting that their PTH levels were relatively unaffected by VitD3 supplementation.

However, one participant had a PTH index of 1.5 – consistent with a diagnosis of secondary

hyperparathyroidism in the VitD deficient state before VitD3 supplementation. The correlation

coefficient was higher when we plotted the PTH index as a function of baseline total 25(OH)D

levels prior to receiving VitD3 supplementation (R^2=0.23; p=2E-06) (Fig. 7C) compared to the

correlation of baseline PTH levels with baseline 25(OH)D levels (R^2=0.08; p=5E-05) (Fig. 7A).

Furthermore, the slope was negative for the graph of PTH index as a function of baseline total

25(OH)D levels as expected based on the known physiology. We also investigated the correlation

of the PTH index with three VitD metabolite ratios. While the correlation coefficient for the

correlation of PTH index with 1,25(OH)$_2$D/24,25(OH)$_2$D was 0.60 (R^2=0.36; p=0.0002) (Fig.

7D), it was 0.44 for 25(OH)D/1,25(OH)$_2$D ratio (R^2=0.20; p=0.0001) (Fig. 7E) and 0.35 for the

24,25(OH)$_2$D/25(OH)D ratio (R^2=0.12; p=2E-06) (Fig. 7F). We conducted a sensitivity analysis

by investigating the impact of removing the single participant whose PTH index was outside the

range of 0.8-1.2. When we removed data from that participant, the correlation coefficient for the

PTH index versus the $1,25(OH)_2D/24,25(OH)_2D$ ratio decreased from 0.60 (p=0.0002) to 0.21

(p=0.0003) (Fig. 7D). Similar decreases were observed for the values of correlation coefficients

for other indices of VitD status (Figs. 7E and 7F).

DISCUSSION

Claude Bernard noted in the 19th century that "*stability of the internal environment (milieu*

intérieur) is a condition for a free and independent life" (10). Later, in the early 20th century,

Walter B. Cannon coined the term "*homeostasis"* to describe mechanisms that maintain the

stability of the *milieu intérieur* (9, 10). Because of the critical importance of Ca^{+2} in many

biological processes, the "*Wisdom of the Body"* (9, 10) has evolved multiple homeostatic

mechanisms to maintain free serum Ca^{+2} levels within a narrow physiological range. Since VitD

plays a critical role in mediating intestinal absorption of dietary Ca^{+2}, homeostatic mechanisms

also maintain free $1,25(OH)_2D$ within narrow physiological ranges. To maintain stable levels of

$1,25(OH)_2D$ when VitD availability is scarce, the body has two defense mechanisms: (1) to

increase production of $1,25(OH)_2D$ by increasing PTH-induced 1α-hydroxylation of 25(OH)D

(12, 16, 17) and/or (2) to decrease the metabolic clearance of $1,25(OH)_2D$ by suppressing 24-

hydroxylase – the enzyme which degrades $1,25(OH)_2D$ and 25(OH)D (14, 15). However, as

noted in The Endocrine Society's clinical practice guidelines, VitD deficiency-induced

secondary hyperparathyroidism is associated with adverse effects on bone health: VitD-induced

secondary hyperparathyroidism has an adverse impact on bone health by increasing "*osteoclastic*

activity thereby creating local foci of bone weakness, which causes a generalized decrease in

bone mineral density, resulting in osteopenia and osteoporosis" (17).

Two lines of defense to maintain physiological levels of $1,25(OH)_2D$

Based on our study's inclusion criteria, all research participants met The Endocrine Society's

criterion for VitD deficiency [i.e., screening 25(OH)D ≤ 20 ng/mL]. While total 25(OH)D and

$24,25(OH)_2D$ levels were increased significantly by VitD3 supplementation, total $1,25(OH)_2D$

did not change. Moreover, levels of PTH were within normal limits at baseline and did not

change when supplements were administered to correct the VitD deficiency. These data are

consistent with published evidence suggesting that mild-moderate VitD deficiency may not

trigger secondary hyperparathyroidism while secondary hyperparathyroidism is a characteristic

feature of severe VitD deficiency [25(OH)D <10-12 ng/mL] (35-37).

The published literature contains many graphs displaying PTH levels as a function of total

25(OH)D (35, 38-41). In general, these graphs depict an increase in mean PTH levels as

25(OH)D levels decrease with an inflection point at total 25(OH)D levels in the range between

20-30 ng/mL (37). However, individual data points scatter widely above and below the mean

values for PTH. If one focuses on mean data, one might conclude that all individuals are

gradually becoming increasingly hyperparathyroid as total 25(OH)D decreases. However,

detailed analysis of the data suggests an alternative interpretation. If one examines data points

corresponding to 25(OH)D levels in the range of 10-20 ng/mL, the vast majority of individual

data points span the same range of PTH levels even as 25(OH)D levels decrease. However, the

number of outliers (i.e., elevated PTH levels) begins to increase as 25(OH)D levels decrease

below ~20 ng/mL. We interpret this observation as suggesting that there is considerable inter-

individual variation in the setpoint for developing secondary hyperparathyroidism. When

25(OH)D levels fall below ~10 ng/mL, there is a substantial increase in both the mean level of

PTH and the percentage of individuals with secondary hyperparathyroidism. Although the

explanation of the shape of the graph is not entirely clear, we hypothesize that inter-individual

variation in VDBP levels may be an important contributor. Individuals with high VDBP levels

are predicted to have lower free 25(OH)D levels at any given level of total 25(OH)D. Thus, such

individuals with high VDBP levels would be predicted to develop secondary

hyperparathyroidism at higher levels of total 25(OH)D. Accordingly, we hypothesize that VDBP-

independent indices of VitD status would better predict development of secondary

hyperparathyroidism. Tang et al provided data suggesting that the $1,25(OH)_2D/24,25(OH)_2D$

ratio >100 is associated with an increased risk of elevated PTH level. Our data are consistent

with the hypothesis that the $1,25(OH)_2D/24,25(OH)_2D$ ratio may be better correlated with

secondary hyperparathyroidism as compared to other indices of VitD status such as the total

25(OH)D level.

The absence of secondary hyperparathyroidism in our participants with mild-moderate VitD

deficiency inspired us to investigate what other homeostatic mechanisms maintained

$1,25(OH)_2D$ in the normal range. Analysis of our data demonstrated that the correlation between

25(OH)D and $24,25(OH)_2D$ levels was defined by a sigmoid curve rather than a hyperbola.

Based on this observation, we hypothesized that 24-hydroxylase expression is regulated, and we

designed a mathematical model to test our hypothesis. Our model demonstrates that 24-

hydroxylase activity achieves a minimum (~90% suppression) when 25(OH)D levels <10-20

ng/mL. Thus, in mild-moderate VitD deficiency, the body suppresses 24-hydroxylation to

preserve $1,25(OH)_2D$ from degradation and this mechanism provides the first line of defense

against VitD deficiency. Interestingly, viewed from a different perspective, high levels of

25(OH)D are associated with increased 24-hydroxylase activity, which provides a major defense

against VitD toxicity. In the absence of secondary hyperparathyroidism, it is possible that mild-

moderate VitD deficiency may not represent an absolute requirement for treatment with VitD

supplements if the treatment objective is to promote bone health. On the other hand, recent

publications have suggested that $24,25(OH)_2D$ exerts a direct effect to promote healing of bone

fractures (42-44). In other words, whether or not mild-moderate VitD deficiency increases the

risk of bone fracture, it has been proposed that adequate levels of $24,25(OH)_2D$ may promote

healing of bone fractures.

Considerable controversy exists with respect to the overall health impact of VitD status and VitD

supplementation in the general population (45-48). Published literature demonstrates that severe

VitD deficiency triggers secondary hyperparathyroidism, which in turn induces 1α-hydroxylation

– thereby increasing the rate of $1,25(OH)_2D$ biosynthesis (16, 35). Because secondary

hyperparathyroidism is not triggered unless VitD deficiency becomes severe [e.g., 25(OH)D

<10-12 ng/mL] or if 1α-hydroxylation is impaired as in chronic kidney disease, this mechanism

provides the second line of defense against VitD deficiency. Secondary hyperparathyroidism is

associated with adverse effects on bone health. This provides a strong rationale for treatment

with VitD supplements. We propose two diagnostic terms to reflect clinical differences between

these two scenarios. "Sub-clinical VitD deficiency" describes a clinical condition when only the

first line of defense (suppression of 24-hydroxylase) has been triggered. "Overt VitD deficiency"

describes a clinical condition when both lines of defense are triggered (i.e., suppression of 24-

hydroxylase plus secondary hyperparathyroidism). This is consistent with conclusions of a

scientific workshop sponsored by the National Kidney Foundation in 2018, which suggested that

in patients with chronic kidney disease, 25(OH)D levels of <15 ng/mL require VitD treatment

and in the range of 15-20 ng/mL, require treatment only if there is evidence of secondary

hyperparathyroidism (22).

Which molecular mechanism(s) mediate homeostatic regulation of 24-hydroxylase activity?

Expression of the *CYP24A1* gene (the gene encoding 24-hydroxylase enzyme) is reported to be

increased by $1,25(OH)_2D$ and FGF23 but decreased by PTH (49). However, mean levels of total

$1,25(OH)_2D$, FGF23, and PTH did not change in response to VitD3 supplementation in our

clinical trial (13). Taken at face value, these observations suggest that regulation of 24-

hydroxylase activity may be mediated by factors other than levels of $1,25(OH)_2D$, FGF23, or

PTH. Nevertheless, it remains possible that regulation of 24-hydroxylase activity is sensitive to

extremely small changes in levels of $1,25(OH)_2D$, FGF23, or PTH, which were not captured in

our study. Furthermore, all three hormones exhibit circadian variation (50-52). Since we obtained

blood samples at only one time of day, we cannot exclude the possibility that the relevant

biomarker(s) might require measurements of circulating levels integrated over a 24-hour period.

In any case, additional research will be required to answer this interesting question.

Implications for clinical diagnosis of VitD deficiency

Although the Endocrine Society's clinical practice guidelines recommend a "one-size-fits-all"

approach based on measurements of total levels of 25(OH)D (17), this approach does not

account for the substantial inter-individual variation in levels of VDBP that limits the

applicability of this approach. Whereas the usual clinical assays primarily reflect protein-bound

levels of VitD metabolites, it is the free levels (i.e., not bound to protein) that are biologically

relevant (53). This provides a strong rationale for a *precision diagnostics* approach wherein

diagnostic criteria for VitD deficiency are adjusted for each individual based on that person's

circulating level of VDBP. Other factors may also be relevant: for example, individual setpoints

for PTH secretion and an individual's sensitivity to biological actions of PTH (54). These

considerations raise challenging questions about how best to implement a precision diagnostics

approach to diagnose VitD deficiency and secondary hyperparathyroidism. Others have

suggested the potential value of using a tailored approach to assess VitD status and to guide

decisions about the need for VitD supplementation (55). In clinical endocrinology practice,

deficiency states are frequently diagnosed by documenting the activation of compensatory

homeostatic mechanisms. For example, hypothyroidism is diagnosed by documenting elevated

levels of TSH. Conversely, hyperthyroidism is diagnosed by documenting suppression of TSH

levels (20). By basing diagnoses on whether the body's homeostatic responses have been

triggered, physicians implicitly rely on Cannon's concept of the "*wisdom of the body"* to

diagnose hormonal status. Following these precedents, one might base the diagnosis of VitD

deficiency on documenting the activation of the relevant homeostatic mechanisms – e.g.,

suppression of 24-hydroxylase activity. However, it is challenging to base the diagnosis solely on

measuring total $24,25(OH)_2D$ levels because of the confounding influence of inter-individual

variation in VDBP levels. The observed threefold inter-individual variation in levels of VDBP

(29) is predicted to cause a three-fold inter-individual variation in total levels of $24,25(OH)_2D$

even in individuals with identical levels of free $24,25(OH)_2D$. Fortunately, VitD metabolite ratios

are known to be independent of VDBP levels (24). Tang et al. (23) have advocated the use of the

$1,25(OH)_2D/24,25(OH)_2D$ ratio for this purpose. As confirmed by our mathematical model (Fig.

4A), VitD deficiency is associated with a dramatic increase in the $1,25(OH)_2D/24,25(OH)_2D$

ratio as a consequence of the marked suppression of 24-hydroxylase activity induced by VitD

deficiency. By providing an index of the level of 24-hydroxylase activity, the

$1,25(OH)_2D/24,25(OH)_2D$ ratio provides a highly sensitive index of clinical VitD status.

Furthermore, because of the extremely high correlation between the $1,25(OH)_2D/24,25(OH)_2D$

ratio and the $25(OH)D/1,25(OH)_2D$ ratio (Fig. 4B), it seems likely that the

$25(OH)D/1,25(OH)_2D$ ratio might also provide a useful clinical assessment of VitD status. This

latter ratio is based on two widely available assays [25(OH)D and $1,25(OH)_2D$] whereas the

$1,25(OH)_2D/24,25(OH)_2D$ ratio requires an assay for $24,25(OH)_2D$, which is currently less

widely available and more expensive. Different VitD metabolite ratios have been suggested for

assessment of VitD status and some studies have investigated their predictive value for hard

clinical endpoints e.g., risk of bone fracture (31, 33). The 24,25(OH)$_2$D/25(OH)D ratio has

gained attention as a clinically informative substitute for total plasma 25(OH)D for assessment of

VitD status. Furthermore, the scientific workshop sponsored by the National Kidney Foundation

proposed that the 24,25(OH)$_2$D/25(OH)D ratio might be particularly useful in patients with CKD

as a surrogate for activity of 24-hydroxylase, as in this patient population 1α-hydroxylation of

25(OH)D is impaired (22).

Interindividual variation in PTH levels

Even in VitD-replete participants being treated with VitD3 supplements, we observed a wide

range of PTH levels (29-85pg/mL). Furthermore, mean levels of PTH were not significantly

affected by administration of VitD3 supplements in our study (47.5±4.8 pg/mL before and

48.4±5.1 pg/mL after VitD3 supplementation). As suggested by others (56), interindividual

variation in PTH levels may reflect variation in the setpoint for PTH secretion. Variation in

dietary calcium intake may also affect PTH levels (57). These considerations create major

challenges in how to interpret an individual measurement of PTH. We, therefore, assessed the

response of PTH to VitD3 supplementation as an indication of whether a participant exhibited

secondary hyperparathyroidism due to VitD deficiency. While one participant exhibited a ~34%

decrease in PTH level in response to VitD3 supplementation, the other participants did not

exhibit significant suppression of PTH levels in response to VitD3 supplementation. We

compared the performance of various indices of VitD status as predictors of secondary

hyperparathyroidism. Among the indices of VitD status, the 1,25(OH)$_2$D/24,25(OH)$_2$D ratio was

the most highly correlated with our index of secondary hyperparathyroidism (R^2=0.36;

p=0.0002). However, none of the indices of VitD status accounted for more than 36% of the

variance in our index of secondary hyperparathyroidism – most likely, because only one of our

11 participants had any evidence suggestive of secondary hyperparathyroidism. In contrast, the

1,25(OH)$_2$D/24,25(OH)$_2$D ratio was highly correlated (ρ^2=-0.94; p=3E-13) with relative 24-

hydroxylase activity as calculated by our mathematical model – accounting for 94% of the

variance in relative 24-hydroxylase activity. Other indices were less well correlated:

24,25(OH)$_2$D/25(OH)D (ρ^2=0.67; p=3E-06) and total 25(OH)D (ρ^2=0.72; p=7E-07).

Study design: strengths and limitations

The study was designed as a crossover study to enable paired statistical analyses comparing data

obtained before versus after administration of VitD3 supplements. To minimize the impact of

circadian rhythms for plasma 1,25(OH)$_2$D, PTH, and FGF23 (50-52), all blood samples were

obtained at the same time of day (~7:00 am). Using LC-MS/MS-based assays of VitD

metabolites (Quest Diagnostics and Heartland Assays), we did not detect metabolites of VitD2 in

any of our participants. The absence of VitD2 metabolites simplified data interpretation by

avoiding potential issues related to differences between VitD2 and VitD3 (58). Data on levels of

25(OH)D and 24,25(OH)$_2$D were provided by Heartland Assays – a company that specializes in

applying liquid chromatography and mass spectroscopy (LC-MS/MS) to conduct scientifically

rigorous and reproducible assays of VitD metabolites. Our novel mathematical model provided

quantitative estimates of *in vivo* 24-hydroxylase activity and represents another strength of the

study. Furthermore, while previous publications provide data on one or another ratio of VitD

metabolites (22, 24, 30, 31), our analysis compares the predictive value of three VitD metabolite

ratios: 1,25(OH)$_2$D/24,25(OH)$_2$D; 25(OH)D/1,25(OH)$_2$D; and 24,25(OH)$_2$D/25(OH)D.

In addition to these strengths of our study design, the study had important limitations. Although

our original study design proposed to study 25 participants, the impact of the COVID-19

pandemic necessitated a decrease in the sample size to 11 participants. Limitations associated

with the relatively small sample size are partially mitigated by our efforts to assure scientific

rigor and reproducibility of the primary data – e.g., the enhanced statistical power provided by

conducting paired statistical comparisons. Accordingly, many of our analyses [e.g., VitD-induced

changes in 25(OH)D and 24,25(OH)$_2$D] demonstrated high levels of statistical significance.

Other analyses [e.g., comparisons for 1,25(OH)$_2$D and PTH] demonstrated essentially identical

mean values before and after VitD3 supplementation. Based on clinical guidelines of The

Endocrine Society, all of our participants exhibited some degree of VitD deficiency. However,

only one participant exhibited more severe VitD deficiency accompanied by secondary

hyperparathyroidism. Additional research will be required to better understand VitD homeostatic

mechanisms in patients with severe VitD deficiency.

Finally, this study was designed as an outpatient study with participants free to eat *ad libitum*.

Day-to-day variation in dietary intake of calcium and phosphate may have increased variation in

measurements of various endpoints – e.g., PTH or FGF23. Furthermore, since our study design

did not include data on dietary intake, our analysis could not investigate dietary factors as

covariates. We have offered some tentative hypotheses related to the necessity of VitD

supplements in overt VitD deficiency as compared to the possible optional nature of VitD

supplements in sub-clinical VitD deficiency. However, we acknowledge that the present study

does not provide sufficient data to draw rigorous evidence-based conclusions with respect to

treatment recommendations. Our small pilot study is based on biomarker data rather than hard

clinical outcomes. Future research will be required to address these important clinical questions.

Nevertheless, we believe it is valuable to offer hypotheses based on implications derived from

consideration of underlying physiology and pathophysiology.

Acknowledgements

The authors gratefully acknowledge research funding provided by NIDDK and the NIH Office of

597
598
Dietary Supplements: R01DK118942, R01DK118942-02S1, and T32DK098107. We are also

599
grateful to the staff at University of Maryland's Amish Research Clinic and to the members of the

600
Old Order Amish Community in Lancaster, PA who participated in this clinical trial.

Data Availability

602
Primary data will be made available upon request to qualified academic investigators for research

603
purposes under a Data Transfer Agreement to protect research participants' confidential

604
information.

605 **Table 1. Parameters of the mathematical model.**

Model parameters	Definitions
α	A model parameter to facilitate fitting the equation to the observed data
h	Relative 24-hydroxylase activity
$K1$	Michaelis-Menten constant for 1α-hydroxylase with 25(OH)D as substrate
K_{24}	Michaelis-Menten constant for 24-hydroxylase enzyme with 25(OH)D as substrate (to fit hyperbolic curve)
$L_{1,25}$	Analog of Michaelis-Menten constant for 24-hydroxylase enzyme with 1,25(OH)$_2$D as substrate (to fit sigmoid curve)
L_{24}	Analog of Michaelis-Menten constant for 24-hydroxylase enzyme with 25(OH)D as substrate (to fit sigmoid curve)
$m(1,25)$	First order rate constant for metabolic clearance of 1,25(OH)$_2$D
$m(24,25)$	First order rate constant for metabolic clearance of 24,25(OH)$_2$D
$S(1,25)$	1,25(OH)$_2$D concentration
$S(24,25)$	24,25(OH)$_2$D concentration
$S(25)$	25(OH)D concentration
$V1$	Maximal velocity for 1α-hydroxylase with 25(OH)D as substrate
V_{24}	Maximal velocity for 24-hydroxylase with 25(OH)D as substrate (to fit hyperbolic curve)
$W_{1,25}$	Maximal velocity for 24-hydroxylase with 1,25(OH)$_2$D as substrate (to fit sigmoid curve)
W_{24}	Maximal velocity for 24-hydroxylase with 25(OH)D as substrate (to fit sigmoid curve)

607   **Table 2. Goodness of fit for mathematical model equations**. The Table includes metrics for the

608   goodness of fit for the modeling equations for 1,25(OH)$_2$D (Fig. 2A) and 24,25(OH)$_2$D (Fig. 2B)

609   as well as the goodness of fit for modeling of three VitD metabolite ratios (Figs. 4A, 5A, and

610   5B).

	24,25(OH)D	1,25(OH)$_2$D	1,25(OH)$_2$D/ 24,25(OH)$_2$D	25(OH)D/ 1,25(OH)$_2$D	24,25(OH)$_2$D/ 25(OH)D
Sum of squares due to regression (SSR) [a]	113	315	809	3.37	0.150
Total sum of squares about mean (SST) [b]	105	3341	849	3.22	0.151
Sum of squared errors (SSE) [c]	8.2	3483	412	1.66	0.079
Ratio of SSE/SST	0.078	1.04	0.49	0.52	0.52
Ratio of SSR/SST	1.08	0.094	0.95	1.05	0.995

[a] $SSR = \sum(\hat{x}_i - \bar{x})^2$

[b] $SST = \sum(x_i - \bar{x})^2$

[c] $SSE = \sum(x_i - \hat{x}_i)^2$

Where x_i represents individual observed total levels of VitD metabolites, $\hat{x}_i$ represents individual
predicted total levels of VitD metabolites, and $\bar{x}$ represents the mean of observed total levels of
VitD metabolites.

Figure 1. Impact of VitD3 supplementation on total levels of VitD metabolites. Healthy

participants (N=11) were recruited based on meeting the Endocrine Society's criterion of VitD

deficiency [25(OH)D ≤20 ng/mL]. Total levels of VitD metabolites were assayed before and after

participants received VitD3 supplements (13): 25(OH)D (panel A), 24,25(OH)$_2$D (panel B), and

1,25(OH)$_2$D (panel C). Data are presented as means ± SEM; p-values were calculated using a

two-tailed t-test for paired data.

Figure 2. Total levels of 1,25(OH)$_2$D and 24,25(OH)$_2$D as a function of total levels of

25(OH)D. Panels A and B present pooled data for individual participants when they were VitD

deficient (gray circles) and after they received VitD3 supplements (black circles). 1,25(OH)$_2$D

(panel A) and 24,25(OH)$_2$D (panel B) are plotted as a function of total levels of 25(OH)D. The

text box in panel B presents the Spearman correlation coefficient (ρ). The curves represent the

equations derived from our mathematical model: equation (1) in Panel A and equation (7) in

Panel B. Values of parameters for Equation (1): W_{24}=8 ng/mL; L_{24}=40 ng/mL; and α=0.1. Values

for parameters for Equation (7): $W_{1,25}$=40 ng/mL; $L_{1,25}$=60 ng/mL; V_1=40; K=60 ng/mL; α=0.1;

and $m_{1,25}$=1.

Figure 3. Assumptions underlying mathematical model: regulation of 24-hydroxylase

activity in response to clinical VitD status. Panel A depicts curves corresponding to equations

(1) and (2) [sigmoid and hyperbola, respectively]. Panel B depicts a family of hyperbolas

[equation (2)] corresponding to varying degrees of induction from 10-100% of maximal

induction of 24-hydroxylase activity. Panel C depicts equation (3), which is the fractional

induction of 24-hydroxylase activity relative to the maximal level of induction as a function of

25(OH)D. Values of parameters for Equation (1): W_{24}=8 ng/mL; L_{24}=40 ng/mL; and α=.0.1.

Values for parameters for Equation (2): V_{24}=10 and K_{24}=20 ng/mL. Values of parameters for

Equation (3) m(24,25)=1; other parameters the same as for Equations (1) and (2).

Figure 4. The 1,25(OH)$_2$D/24,25(OH)D and 25(OH)D/1,25(OH)$_2$D ratios reflect clinical

VitD status. The graphs summarize data from individual participants when they were VitD

deficient (gray circles) and after they received VitD3 supplements (black circles). Panel A depicts

the 1,25(OH)$_2$D/24,25(OH)$_2$D ratio as a function of total 25(OH)D. The modeled curve was

calculated as the ratio of modeled values for 1,25(OH)$_2$D [equation (7)] divided by modeled

values of 24,25(OH)$_2$D [equation (1)]. Panel B depicts 1,25(OH)$_2$D/24,25(OH)$_2$D ratio as a

function of 25(OH)D/1,25(OH)$_2$D ratio. The fitted curves were calculated by GraphPad Prism

software. Text boxes indicate Spearman correlation coefficients and p-values for the correlations.

Figure 5. VitD metabolite ratios [25(OH)D/1,25(OH)$_2$D and 24,25(OH)$_2$D/25(OH)D] as a

function of the total levels of 25(OH)D. The graphs summarize data from individual

participants when they were VitD deficient (gray circles) and after they received VitD3

supplements (black circles). Panel A depicts the 25(OH)D/1,25(OH)$_2$D ratio as a function of total

25(OH)D. The modeled curve was calculated as a linear regression using GraphPad Prism

software. Panel B depicts 24,25(OH)$_2$D/25(OH)D ratio as a function of 25(OH)D. The modeled

curve was calculated as modeled values for 24,25(OH)$_2$D [equation (1)] divided by assumed

values of 25(OH)D.

Figure 6. Correlation between relative 24-hydroxylase activity (*h*) and indices of VitD

status. Panels A-D present pooled data when participants were VitD deficient (gray circles) and

after they received VitD3 supplementation (black circles). The text boxes below the panels

present two Spearman correlation coefficients and two p-values. The first bullet points

correspond to the correlation between 24-hydroxylase and each of the VitD status indices at

baseline before participants received VitD3 supplementation. The second bullet points

correspond to the correlation between 24-hydroxylase and each of the VitD status indices based

on the pooled data (both before and after VitD3 supplementation). The curves in the graphs were

based on modeling of the pooled data.

Figure 7. Correlation between PTH and different indices of VitD status. Panels A and B

depict correlations of baseline PTH levels with baseline total 25(OH)D (panel A) or baseline

1,25(OH)$_2$D/24,25(OH)$_2$D ratio (panel B) before participants received VitD3 supplementation.

Panel C depicts the correlation between the PTH index (PTH level before VitD3 supplementation

divided by PTH level after VitD3 supplementation) and baseline total 25(OH)D. Panels D, E, and

F depict correlations between the PTH index and other indices of VitD status:

1,25(OH)$_2$D/24,25(OH)$_2$D ratio (panel D), 25(OH)D/1,25(OH)$_2$D ratio (panel E), and

24,25(OH)$_2$D/25(OH)D ratio (panel F). The solid black lines correspond to least-squares fits for

all 11 data points. Gray dotted lines in panels C-F correspond to a sensitivity analysis conducted

by removing the participant who had the highest $1,25(OH)_2D/24,25(OH)_2D$ ratio and PTH index.

That participant is shown by a gray square in the panels C-F. The text boxes below panels C-F

present equations and p-values corresponding to the gray dotted lines.

REFERENCES

1. Christakos S, Dhawan P, Porta A, Mady LJ, and Seth T. Vitamin D and intestinal calcium absorption. *Mol Cell Endocrinol.* 2011;347(1-2):25-9.

2. Fleet JC. Vitamin D-Mediated Regulation of Intestinal Calcium Absorption. *Nutrients.* 2022;14(16).

3. Christakos S, Li S, De La Cruz J, Shroyer NF, Criss ZK, Verzi MP, et al. Vitamin D and the intestine: Review and update. *J Steroid Biochem Mol Biol.* 2020;196:105501.

4. Fleet JC. The role of vitamin D in the endocrinology controlling calcium homeostasis. *Mol Cell Endocrinol.* 2017;453:36-45.

5. Chick HD, E.G.; Hume, M.; Mackay, H.M.M.; Smith, H.H.; Wimberger, H. The aetiology of rickets in infants: Prophylactic and curative observations at the Vienna University Kinderklinik. *The Lancet.* 1922:7-11.

6. Rajakumar K. Vitamin D, cod-liver oil, sunlight, and rickets: a historical perspective. *Pediatrics.* 2003;112(2):e132-5.

7. Miller WL, and Imel EA. Rickets, Vitamin D, and Ca/P Metabolism. *Horm Res Paediatr.* 2022;95(6):579-92.

8. Bikle DD. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al. eds. *Endotext.* South Dartmouth (MA): MDText.com, Inc. Copyright © 2000-2023, MDText.com, Inc.; 2000.

9. Cannon WB. *The wisdom of the body.* Norton and Company Limited, W. W.; 1963.

10. Davies KJ. Adaptive homeostasis. *Mol Aspects Med.* 2016;49:1-7.

11.   Holick MF. Vitamin D status: measurement, interpretation, and clinical application. *Ann*

Epidemiol. 2009;19(2):73-8.

12.   Young K, Beggs MR, Grimbly C, and Alexander RT. Regulation of 1 and 24

hydroxylation of vitamin D metabolites in the proximal tubule. *Exp Biol Med*

(Maywood). 2022;247(13):1103-11.

13.   Shahidzadeh Yazdi Z, Streeten EA, Whitlatch HB, Montasser ME, Beitelshees AL, and

Taylor SI. Vitamin D deficiency increases vulnerability to canagliflozin-induced adverse

effects on 1,25-dihydroxyvitamin D and PTH. *J Clin Endocrinol Metab.* 2023.

14.   Jones G, Strugnell SA, and DeLuca HF. Current understanding of the molecular actions

of vitamin D. *Physiol Rev.* 1998;78(4):1193-231.

15.   Jones G, Prosser DE, and Kaufmann M. 25-Hydroxyvitamin D-24-hydroxylase

(CYP24A1): its important role in the degradation of vitamin D. *Arch Biochem Biophys.*

2012;523(1):9-18.

16.   Brenza HL, Kimmel-Jehan C, Jehan F, Shinki T, Wakino S, Anazawa H, et al. Parathyroid

hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter.

Proc Natl Acad Sci U S A. 1998;95(4):1387-91.

17.   Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et

al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society

clinical practice guideline. *J Clin Endocrinol Metab.* 2011;96(7):1911-30.

18.   Tanaka Y, and DeLuca HF. Stimulation of 24,25-dihydroxyvitamin D3 production by

1,25-dihydroxyvitamin D3. *Science.* 1974;183(130):1198-200.

19. Tahaka Y, Lorenc RS, and DeLuca HF. The role of 1,25-dihydroxyvitamin D3 and

parathyroid hormone in the regulation of chick renal 25-hydroxyvitamin D3-24-

hydroxylase. *Arch Biochem Biophys.* 1975;171(2):521-6.

20. Ladenson PW. Diseases of the thyroid gland. *Clin Endocrinol Metab.* 1985;14(1):145-73.

21. Raff H, and Carroll T. Cushing's syndrome: from physiological principles to diagnosis

and clinical care. *J Physiol.* 2015;593(3):493-506.

22. Melamed ML, Chonchol M, Gutiérrez OM, Kalantar-Zadeh K, Kendrick J, Norris K, et

al. The Role of Vitamin D in CKD Stages 3 to 4: Report of a Scientific Workshop

Sponsored by the National Kidney Foundation. *Am J Kidney Dis.* 2018;72(6):834-45.

23. Tang JCY, Jackson S, Walsh NP, Greeves J, and Fraser WD. The dynamic relationships

between the active and catabolic vitamin D metabolites, their ratios, and associations with

PTH. *Sci Rep.* 2019;9(1):6974.

24. Ginsberg C, Hoofnagle AN, Katz R, Becker JO, Kritchevsky SB, Shlipak MG, et al. The

Vitamin D Metabolite Ratio Is Independent of Vitamin D Binding Protein Concentration.

Clin Chem. 2021;67(2):385-93.

25. Biancuzzo RM, Clarke N, Reitz RE, Travison TG, and Holick MF. Serum concentrations

of 1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 in response to vitamin D2

and vitamin D3 supplementation. *J Clin Endocrinol Metab.* 2013;98(3):973-9.

26. Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, John U, et al. Mutations in

CYP24A1 and idiopathic infantile hypercalcemia. *N Engl J Med.* 2011;365(5):410-21.

27. Streeten EA, Zarbalian K, and Damcott CM. CYP24A1 mutations in idiopathic infantile

hypercalcemia. *N Engl J Med.* 2011;365(18):1741-2; author reply 2-3.

28. Batacchi Z, Robinson-Cohen C, Hoofnagle AN, Isakova T, Kestenbaum B, Martin KJ, et

al. Effects of Vitamin D(2) Supplementation on Vitamin D(3) Metabolism in Health and

CKD. *Clin J Am Soc Nephrol.* 2017;12(9):1498-506.

29. Robinson-Cohen C, Zelnick LR, Hoofnagle AN, Lutsey PL, Burke G, Michos ED, et al.

Associations of Vitamin D-Binding Globulin and Bioavailable Vitamin D Concentrations

With Coronary Heart Disease Events: The Multi-Ethnic Study of Atherosclerosis

(MESA). *J Clin Endocrinol Metab.* 2017;102(8):3075-84.

30. Ahmed LHM, Butler AE, Dargham SR, Latif A, Chidiac OM, Atkin SL, et al. Vitamin

D(3) metabolite ratio as an indicator of vitamin D status and its association with diabetes

complications. *BMC Endocr Disord.* 2020;20(1):161.

31. Ginsberg C, Hoofnagle AN, Katz R, Hughes-Austin J, Miller LM, Becker JO, et al. The

Vitamin D Metabolite Ratio Is Associated With Changes in Bone Density and Fracture

Risk in Older Adults. *J Bone Miner Res.* 2021;36(12):2343-50.

32. Meng L, Su C, Shapses SA, and Wang X. Total and free vitamin D metabolites in patients

with primary hyperparathyroidism. *J Endocrinol Invest.* 2022;45(2):301-7.

33. Bansal N, Katz R, Appel L, Denburg M, Feldman H, Go AS, et al. Vitamin D Metabolic

Ratio and Risks of Death and CKD Progression. *Kidney Int Rep.* 2019;4(11):1598-607.

34. Ginsberg C, Katz R, de Boer IH, Kestenbaum BR, Chonchol M, Shlipak MG, et al. The

24,25 to 25-hydroxyvitamin D ratio and fracture risk in older adults: The cardiovascular

health study. *Bone.* 2018;107:124-30.

35. Jesudason D, Need AG, Horowitz M, O'Loughlin PD, Morris HA, and Nordin BE.

Relationship between serum 25-hydroxyvitamin D and bone resorption markers in

vitamin D insufficiency. *Bone.* 2002;31(5):626-30.

36.   Jones G. 100 YEARS OF VITAMIN D: Historical aspects of vitamin D. *Endocr Connect.*

2022;11(4).

37.   Rosen CJ, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, et al.

IOM committee members respond to Endocrine Society vitamin D guideline. *J Clin*

Endocrinol Metab. 2012;97(4):1146-52.

38.   Mendes MM, Hart KH, Lanham-New SA, and Botelho PB. Suppression of Parathyroid

Hormone as a Proxy for Optimal Vitamin D Status: Further Analysis of Two Parallel

Studies in Opposite Latitudes. *Nutrients.* 2020;12(4).

39.   Looker AC, and Gunter EW. Hypovitaminosis D in medical inpatients. *N Engl J Med.*

1998;339(5):344-5; author reply 5-6.

40.   Shah S, Chiang C, Sikaris K, Lu Z, Bui M, Zebaze R, et al. Serum 25-Hydroxyvitamin D

Insufficiency in Search of a Bone Disease. *J Clin Endocrinol Metab.* 2017;102(7):2321-

8.

41.   Gallagher JC, Jindal PS, and Smith LM. Vitamin D supplementation in young White and

African American women. *J Bone Miner Res.* 2014;29(1):173-81.

42.   Demay MB. The good and the bad of vitamin D inactivation. *J Clin Invest.*

2018;128(9):3736-8.

43.   Martineau C, Kaufmann M, Arabian A, Jones G, and St-Arnaud R. Preclinical safety and

efficacy of 24R,25-dihydroxyvitamin D(3) or lactosylceramide treatment to enhance

fracture repair. *J Orthop Translat.* 2020;23:77-88.

44.   Martineau C, Naja RP, Husseini A, Hamade B, Kaufmann M, Akhouayri O, et al. Optimal

bone fracture repair requires 24R,25-dihydroxyvitamin D3 and its effector molecule

FAM57B2. *J Clin Invest.* 2018;128(8):3546-57.

45.   Bouillon R, Manousaki D, Rosen C, Trajanoska K, Rivadeneira F, and Richards JB. The

health effects of vitamin D supplementation: evidence from human studies. *Nat Rev*

Endocrinol. 2022;18(2):96-110.

46.   Cummings SR, and Rosen C. VITAL Findings - A Decisive Verdict on Vitamin D

Supplementation. *N Engl J Med.* 2022;387(4):368-70.

47.   LeBoff MS, Chou SH, Ratliff KA, Cook NR, Khurana B, Kim E, et al. Supplemental

Vitamin D and Incident Fractures in Midlife and Older Adults. *N Engl J Med.*

2022;387(4):299-309.

48.   Pfotenhauer KM, and Shubrook JH. Vitamin D Deficiency, Its Role in Health and

Disease, and Current Supplementation Recommendations. *J Am Osteopath Assoc.*

2017;117(5):301-5.

49.   Meyer MB, and Pike JW. Mechanistic homeostasis of vitamin D metabolism in the

kidney through reciprocal modulation of Cyp27b1 and Cyp24a1 expression. *J Steroid*

Biochem Mol Biol. 2020;196:105500.

50.   Blau JE, Bauman V, Conway EM, Piaggi P, Walter MF, Wright EC, et al. Canagliflozin

triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a

randomized crossover study. *JCI Insight.* 2018;3(8).

51.   el-Hajj Fuleihan G, Klerman EB, Brown EN, Choe Y, Brown EM, and Czeisler CA. The

parathyroid hormone circadian rhythm is truly endogenous--a general clinical research

center study. *J Clin Endocrinol Metab.* 1997;82(1):281-6.

52.   Kawai M, Kinoshita S, Shimba S, Ozono K, and Michigami T. Sympathetic activation

induces skeletal Fgf23 expression in a circadian rhythm-dependent manner. *J Biol Chem.*

2014;289(3):1457-66.

53.   Bikle DD. The Free Hormone Hypothesis: When, Why, and How to Measure the Free

Hormone Levels to Assess Vitamin D, Thyroid, Sex Hormone, and Cortisol Status. *JBMR*

Plus. 2021;5(1):e10418.

54.   Lemoine S, Figueres L, Bacchetta J, Frey S, and Dubourg L. Calcium homeostasis and

hyperparathyroidism: Nephrologic and endocrinologic points of view. *Ann Endocrinol*

(Paris). 2022;83(4):237-43.

55.   Bilezikian JP, Formenti AM, Adler RA, Binkley N, Bouillon R, Lazaretti-Castro M, et al.

Vitamin D: Dosing, levels, form, and route of administration: Does one approach fit all?

Rev Endocr Metab Disord. 2021;22(4):1201-18.

56.   Robinson-Cohen C, Lutsey PL, Kleber ME, Nielson CM, Mitchell BD, Bis JC, et al.

Genetic Variants Associated with Circulating Parathyroid Hormone. *J Am Soc Nephrol.*

2017;28(5):1553-65.

57.   Rejnmark L, Vestergaard P, Heickendorff L, and Mosekilde L. Determinants of plasma

PTH and their implication for defining a reference interval. *Clin Endocrinol (Oxf).*

2011;74(1):37-43.

58.   Tripathi A, Ansari M, Dandekar P, and Jain R. Analytical methods for 25-hydroxyvitamin

D: advantages and limitations of the existing assays. *J Nutr Biochem.* 2022;109:109123.

A 1,25(OH)$_2$D vs. 25(OH)D

B 24,25(OH)$_2$D vs. 25(OH)D

A 1,25(OH)₂D/24,25(OH)₂D vs. 25(OH)D

B 1,25(OH)₂D/24,25(OH)₂D vs. 25(OH)D/1,25(OH)₂D

A

Relative 24-hydroxylase (*h*) vs.
25(OH)D

VitD-Suf
VitD-Def

Spearman correlation coefficients:
- Before VitD3 → 0.51 (p=0.1)
- Pooled data → 0.85 (p=7E-07)

B

Relative 24-hydroxylase vs.
25(OH)D/1,25(OH)$_2$D

Spearman correlation coefficients:
- Before VitD3 → 1.00
- Pooled data → 1.00

C

Relative 24-hydroxylase (*h*) vs.
1,25(OH)$_2$D/24,25(OH)$_2$D

Spearman correlation coefficients:
- Before VitD3 → -0.85 (p=0.001)
- Pooled data → -0.97 (p=3E-13)

D

Relative 24-hydroxylase vs.
24,25(OH)$_2$D/25(OH)D

Spearman correlation coefficients:
- Before VitD3 → 0.37 (p=0.3)
- Pooled data → 0.82 (p=3E-06)